Latest news

• Pfizer’s leukaemia drug Mylotarg backed for use in EU

  Pfizer’ s leukaemia drug Mylotarg backed for use in EU. The CHMP’s positive opinion could see the drug return to market after almost eight years. ... Pfizer kept producing Mylotarg in order to make it available on compassionate use in Europe and this

• Novartis claims FDA breakthrough status for leukaemia treatment

  Also waiting in the wings could be volasertib from Boehringer Ingelheim, which is currently in phase III clinical trials, and Pifzer's Mylotarg, which would be reintroduced to the market after

• Boehringer and Philogen collaborate on acute myeloid leukaemia

  Treatment options for AML are still somewhat limited, however at the end of last year Pfizer's Mylotarg (gemtuzumab ozogamcin) also showed itself to significantly improve overall survival compared to best

• ASH: Pfizer eyes re-launch of Mylotarg

  ASH: Pfizer eyes re-launch of Mylotarg. Data supports drug's use in acute myeloid leukaemia. ... We are engaging in discussions with the FDA and other health authorities to determine the best path forward for Mylotarg", he added.

• AZ buys into ADC sector with $440m Spirogen deal

  After a false start in 2000 with the launch and subsequent withdrawal from the market of Mylotarg (gemtuzumab ozogamicin) from Wyeth (now Pfizer), the ADC field has started to gather pace,